Reena Aggarwal
Reena Aggarwal's purchase track record
Reena Aggarwal has no open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 1/5/2024 | NCDL | $31K | pending | pending | — |
| 11/3/2023 | NCDL | $22K | pending | pending | — |
| 1/21/2022 | NCDL | $2K | pending | pending | — |
| 12/10/2021 | NCDL | $9K | pending | pending | — |
| 11/1/2021 | NCDL | $6K | pending | pending | — |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
NCDL Sets Q3 2026 Earnings Date; Q2 Transcript Released. Nuveen Churchill Direct Lending Corp. has scheduled its third-quarter 2026 earnings release and conference call. Additionally, the full transcript of the second-quarter 2026 earnings call has been published. These updates provide investors with the timeline for upcoming financial results and access to recent management commentary.
Transaction History
| CNS | ▲ Buy | Grant | 375 | $0 | 10/1/2026 | View on chart |
| CNS | ▲ Buy | Grant | 353 | $0 | 7/1/2026 | View on chart |
| CNS | ▲ Buy | Grant | 440 | $0 | 4/1/2026 | View on chart |
| CNS | ▲ Buy | Grant | 436 | $0 | 1/2/2026 | View on chart |
| CNS | ▲ Buy | Grant | 423 | $0 | 10/1/2025 | View on chart |
| CNS | ▲ Buy | Grant | 360 | $0 | 7/1/2025 | View on chart |
| CNS | ▲ Buy | Grant | 341 | $0 | 4/1/2025 | View on chart |
| CNS | ▲ Buy | Grant | 298 | $0 | 1/2/2025 | View on chart |
| CNS | ▲ Buy | Grant | 291 | $0 | 10/1/2024 | View on chart |
| CNS | ▲ Buy | Grant | 383 | $0 | 7/1/2024 | View on chart |
| CNS | ▲ Buy | Grant | 362 | $0 | 4/1/2024 | View on chart |
| NCDL | ▲ Buy | Open Market | 1,741 | $31K | 1/5/2024 | View on chart |
| CNS | ▲ Buy | Grant | 365 | $0 | 1/2/2024 | View on chart |
| NCDL | ▲ Buy | Open Market | 1,213 | $22K | 11/3/2023 | View on chart |
| CNS | ▲ Buy | Grant | 442 | $0 | 10/2/2023 | View on chart |
| CNS | ▲ Buy | Grant | 472 | $0 | 7/3/2023 | View on chart |
| CNS | ▲ Buy | Grant | 433 | $0 | 4/3/2023 | View on chart |
| CNS | ▲ Buy | Grant | 419 | $0 | 1/3/2023 | View on chart |
| CNS | ▲ Buy | Grant | 432 | $0 | 10/3/2022 | View on chart |
| CNS | ▲ Buy | Grant | 429 | $0 | 7/1/2022 | View on chart |
| CNS | ▲ Buy | Grant | 315 | $0 | 4/1/2022 | View on chart |
| NCDL | ▲ Buy | Open Market | 128 | $2K | 1/21/2022 | View on chart |
| CNS | ▲ Buy | Grant | 298 | $0 | 1/3/2022 | View on chart |
| NCDL | ▲ Buy | Open Market | 436 | $9K | 12/10/2021 | View on chart |
| NCDL | ▲ Buy | Open Market | 305 | $6K | 11/1/2021 | View on chart |
| CNS | ▲ Buy | Grant | 325 | $0 | 10/1/2021 | View on chart |
| NCDL | ▲ Buy | Open Market | 612 | $12K | 8/24/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 10, 2026
Cohen & Steers (CNS) eyes Q3 2026 results amid REIT sector resilience
A recent article highlights that REITs are holding up despite rising interest rates, driven by solid fundamentals. Cohen & Steers, Inc. is scheduled to release its third‑quarter 2026 earnings on October 15, providing more detail on its performance. The broader REIT strength may be relevant for CNS as it operates within that market.
Cohen & Steers (CNS) eyes Q3 2026 results amid REIT sector resilience. A recent article highlights that REITs are holding up despite rising interest rates, driven by solid fundamentals. Cohen & Steers, Inc. is scheduled to release its third‑quarter 2026 earnings on October 15, providing more detail on its performance. The broader REIT strength may be relevant for CNS as it operates within that market.